Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors

Pediatric Blood and Cancer

Volumn 55, Issue 7, 2010, Pages 1343-1347

  Amigoni, Maria ^a   Giannattasio, Cristina ^a   Fraschini, Donatella ^a   Galbiati, Marianna ^a   Capra, Anna Clara Maria ^a   Madotto, Fabiana ^a   Cesana, Francesca ^a   Jankovic, Momcilo ^a   Masera, Giuseppe ^a   Mancia, Giuseppe ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Acute lymphoblastic leukemia; Cardiotoxicity; Echocardiography; Heart failure

Indexed keywords

ANTHRACYCLINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVOR; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE WALL; HEART VENTRICLE SEPTUM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CHILD; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; SURVIVORS; YOUNG ADULT;

EID: 78049310953     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22637     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Masera G. Leucemia linfoblastica acuta: Storia di un successo. Riv Ital Pediatr (IJP) 1998; 24: 544-548.
3. Iarussi D, Indolfi P, Galderisi M, et al. Cardiac toxicity after anthracyclines chemotherapy in childhood. Herz 2000; 25: 676-688.
4. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 1990; 4: 3076-3086.
5. Goormaghtigh E, Huart P, Praet M, et al. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 1990; 35: 247-257.
6. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
7. Grenier MA, Lipshultz SE. Epidemiology of anthracyclines cardiotoxicity in children and adults. Semin Oncol 1998; 25: 72-85.
8. Simbre VC, Duffy SA, Dadlani GH, et al. Cardiotoxicity of cancer chemotherapy: Implications for children. Paediatr Drugs 2005; 7: 187-202.
9. Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 2006; 33: S8-S14.
10. Adams MJ, Lipshultz SE. Pathophysiology of anthracyclines- and radiation-associated cardiomyopathies: Implications for screening and prevention. Pediatric Blood Cancer 2005; 44: 600-606.
11. Giantris A, Abdurrahman L, Hinkle A, et al. Anthracyclines induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998; 27: 53-68.
12. Kremer LCM, Van der Pal HJH, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracyclines therapy in children. A systematic review. Ann Oncol 2002; 13: 819-829.
13. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukaemia. J Clin Oncol 2005; 23: 2629-2636.
14. Sorensen K, Levitt GA, Bull C, et al. Late anthracyclines cardiotoxicity after childhood cancer. A prospective longitudinal study. Cancer 2003; 97: 1991-1998.
15. Sorensen K, Levitt G, Bull C, et al. Anthracyclines dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol 1997; 15: 61-68.
16. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracyclines dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 545-550.
17. Barry E, Alvarez JA, Scully RE, et al. Anthracyclines-induced cardiotoxicity: Course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007; 8: 1039-1058.
18. ALL Steering committee of the AIEOP, Paolucci G, Masera G, et al. Treating childhood acute lymphoblastic leukemia (ALL): Summary of ten years' experience in Italy. Med Pediatr Oncol 1989; 17: 83-91.
19. Conter V, Arico M, Valsecchi MG, et al. Long term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982-1995. Leukemia 2000; 14: 2196-2204.
20. Gardin JM, McClelland R, Kitzman D, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001; 87: 1051-1057.
21. De Simone G, Gottdiener JS, Chinali M, et al. Left ventricular mass predicts heart failure not related to previous myocardial infarction: The Cardiovascular Health Study. Eur Heart J 2008; 29: 741-747.
22. McMurray J, Ostergren J, Pfeffer M, et al. CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: Baseline characteristics of patients in the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003; 5: 261-270.
23. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90: 179-185.
24. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555-576.
25. Schannwell CM, Schneppenheim M, Perings S, et al. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002; 98: 33-39.
26. Hudson M, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracyclines cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007; 25: 3635-3643.
27. Lipshultz SE, Lipsitz SR, Mone S, et al. Female gender and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-1743.
28. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-1327.
29. Pratt CB, Ransom JL, Evans WE. Age-related Adriamycin cardiotoxicity in children. Cancer Treat Rep 1978; 62: 1381-1385.
30. Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002; 39: 2005-2011.